5311–0.7111 with all the matrix tablets indicating non-Fickian (anomalous) diffusion as the release mechanism from all the matrix tablets formulated with starch acetate. Plots of percent released versus square
root of time were found to be linear with (R2 > 0.9225) all the matrix tablets formulated indicating that the drug release from these tablets was diffusion controlled. As the starch acetate proportion (%) in the matrix tablets was increased, release rate was decreased, a good linear relationship was observed between percent polymer (starch acetate) and release rate (K0) ( Fig. 1). Glipizide release from the matrix tablets could be controlled by varying the proportion of drug:polymer in CSF-1R inhibitor the matrix. Short term accelerated stability testing was performed. The matrix tablets were packed in screw capped HDPE bottles and were stored at 40 °C ± 2 °C and 75% RH ± 5% RH for 6 months. No visible changes were observed in starch acetate matrix tablets after storage. Drug content and drug release from the matrix tablets were evaluated before and after storage. Drug content of the matrix tablets
before and after storage for 6 months. No significant difference (P > 0.05) was observed in the percent drug content before and after storage for 6 months. The drug release characteristics of all the matrix tablets tested remained unaltered during the storage period. Matrix tablets BIBF 1120 ic50 of glipizide (10 mg) prepared employing starch acetate as matrix former in different proportions gave slow and controlled release over more than 24 h. Drug release was diffusion
controlled and dependent on below strength (%) of starch acetate and type of diluent in the tablets. Non-Fickian diffusion was the release mechanism from these tablets. Good linear relationship was observed between percent of polymer (starch acetate) and release rate (K0) of the matrix tablets. Release rate of the matrix tablets was stable and unaltered during short time accelerated stability study. Starch acetate was found suitable as matrix former for controlled release and the matrix tablets of glipizide formulated employing starch acetate gave controlled release of glipizide over 24 h. All authors have none to declare. The authors thank Sri Ramachandra University, Chennai for providing the necessary facilities to carry out this research work. “
“In current years, combination of different drugs in antihypertension therapy in the form of single-dose is significant alternative that combines effectiveness of blood pressure reduction and a low side effect profile with convenient once-daily dosing to enhance patient compliance.1 Also, because of the lower dose of each antihypertensive drug in a combination, metabolic and clinical adverse effects are decreased.